Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 29 Myeloid 18 Classical hematology 3 Thoracic 2 Lymphoid 2 Dermatologic 2 Sarcoma 1 Other solid neoplasm 1 NET 1 Genitourinary 1 Endocrine 1 CNS 1 Breast 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 31 Magnetic Resonance Spectroscopy 25 pembrolizumab 21 Specimen Handling 18 Nivolumab 17 cabozantinib 14 lenvatinib 12 Everolimus 12 trametinib 11 gallium Ga 68 dotatate 10 dabrafenib 10 Ipilimumab 10 Carboplatin 10 Cisplatin 8 atezolizumab 7 Temozolomide 7 Lutetium-177 7 Capecitabine 7 X-Rays 6 Etoposide 6 surufatinib 5 olaparib 5 lanreotide 5 fluorodopa F 18 5 cemiplimab 5 Vemurafenib 5 Paclitaxel 5 Octreotide 5 Lutetium 5 Fluorodeoxyglucose F18 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

decitabine and cedazuridine drug combination × Endocrine × 1 year × Clear all

NCT05178693 2025-11-24

LANTana

Imperial College London

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡